Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Leases (2023 - 2025)

Kura Oncology (KURA) has disclosed Current Leases for 3 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 32.11% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 32.11% year-over-year, with the annual reading at $1.3 million for FY2025, 32.11% down from the prior year.
  • Current Leases for Q4 2025 was $1.3 million at Kura Oncology, down from $1.4 million in the prior quarter.
  • The five-year high for Current Leases was $2.3 million in Q2 2023, with the low at $1.3 million in Q4 2025.
  • Average Current Leases over 3 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Current Leases plummeted 41.55% in 2024, then surged 39.77% in 2025.
  • Over 3 years, Current Leases stood at $1.5 million in 2023, then increased by 24.9% to $1.9 million in 2024, then plummeted by 32.11% to $1.3 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $1.3 million, $1.4 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.